ASTRAZEN AstraZeneca Pharma India Q1 FY26 results (Apr–Jun 2025) and concall
AstraZeneca India delivered a robust performance in FY25 and started Q1 FY26 with 34% revenue growth, primarily fueled by its dominant Oncology segment. While headline EPS was pressured by a ₹90 crore one-off charge related to plant closure and strategic restructuring, underlying profitability grew by 25%. Management is pivoting heavily toward a 'specialist' model, prioritizing Oncology, Rare Diseases, and Biopharmaceuticals while maintaining high inventory levels to ensure product availability for aggressive growth targets.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 408 | 440 | 480 | 526 |
| EBITDA | 53 | 77 | 86 | 81 |
| Net profit | 38 | 31 | 58 | 56 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
